Premium
Tiagabine: A Novel Drug with a GABAergic Mechanism of Action
Author(s) -
Gram Lennart
Publication year - 1994
Publication title -
epilepsia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.687
H-Index - 191
eISSN - 1528-1167
pISSN - 0013-9580
DOI - 10.1111/j.1528-1157.1994.tb05977.x
Subject(s) - tiagabine , gabaergic , antiepileptic drug , mechanism of action , drug , pharmacology , neuroscience , vigabatrin , anticonvulsant , drug action , epilepsy , medicine , computer science , chemistry , inhibitory postsynaptic potential , psychology , biochemistry , in vitro
Summary: The various possibilities for manipulating the γ‐aminobutyric acid (GABA) system to augment GABAergic inhibition have been surveyed with reference to the relevant antiepileptic compounds that have been successfully or unsuccessfully investigated in relation to these different mechanisms of action. The first clinical studies of tiagabine (TGB), a novel GABA‐uptake inhibitor are now available. These studies utilized a novel design, the enrichment (Amery) design, which is put into perspective compared to classical clinical trial designs. Possible advantages and disadvantages of TGB, as seen at this stage in development, have been identified.